DjiboutiTuberculosis profile
Population  2016 <1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.33 (0.21–0.47) 35 (22–50)
Mortality (HIV+TB only) 0.035 (0.025–0.046) 3.7 (2.7–4.9)
Incidence  (includes HIV+TB) 3.2 (2.4–4) 335 (256–423)
Incidence (HIV+TB only) 0.17 (0.13–0.21) 18 (13–22)
Incidence (MDR/RR-TB)** 0.17 (0.093–0.25) 18 (9.8–27)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.25 (0.19–0.31) 0.86 (0.65–1.1) 1.1 (0.84–1.4)
Males 0.29 (0.21–0.36) 1.8 (1.3–2.2) 2 (1.5–2.5)
Total 0.54 (0.4–0.67) 2.6 (2–3.3) 3.2 (2.4–4)
TB case notifications, 2016  
Total cases notified 2 526
Total new and relapse 2 522
          - % tested with rapid diagnostics at time of diagnosis 56%
          - % with known HIV status 89%
          - % pulmonary 61%
          - % bacteriologically confirmed among pulmonary 79%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.12 (0.07–0.17)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 118 5%
          - on antiretroviral therapy 90 76%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  110
(76–150)
Estimated % of TB cases with MDR/RR-TB 4.3% (2.5–7.3) 35% (25–47)  
% notified tested for rifampicin resistance 43% 60% 2 008
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 80, XDR-TB: 6
Patients started on treatment **** MDR/RR-TB: 71, XDR-TB: 6
Treatment success rate and cohort size Success Cohort
New cases registered in 2015 85% 1 042
Previously treated cases registered in 2015 71% 136
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 21%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
6.4% (5.9–7)
TB financing, 2017  
National TB budget (US$ millions) 1.1
Funding source:  domestic, 100% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data